VWF and Hypercholesterolemia: Basiak et al. [58] demonstrated that alirocumab (150 mg bi-weekly) usedfor 90 days in patients with isolated hypercholesterolemia is associated withsignificatively reduced PAI-1, factor VII, and fibrinogen, compared to thebaseline and control group, and reduced von Willebrand factor (vWF) levelscompared to the baseline.